FOXO4-DRIreddit Research into the FOXO4-DRI peptide, a potent senolytic agent, is rapidly advancing our understanding of cellular senescence and its implications for aging and disease....senolytic peptide FOXO4-DRI. Here, we solve the solution NMR structural ... Furthermore, in vitrostudieshave demonstrated the efficacy ofFOXO4-DRIin ... This peptide, known for its ability to selectively target and eliminate senescent cells, has become a focal point in numerous studies aimed at developing novel therapeutic strategies作者：U Tripathi·2021·被引用次数：7—Researchpaper: Molecular modelling of theFOXO4-TP53 interaction to designsenolytic peptidesfor the elimination of senescent cancer cells.. The core mechanism involves disrupting the interaction between the FOXO4 protein and p53, a critical tumor suppressor. By interfering with this binding, FOXO4-DRI effectively induces apoptosis in senescent cells without harming healthy ones, a key characteristic that distinguishes it from many other senolytic compounds.Senotherapeutics for Brain Aging Management
The scientific community is actively investigating the potential applications of FOXO4-DRI across various fields. Studies have demonstrated its efficacy in clearing senescent cells in diverse contexts, including expanded human chondrocytes, fibroblasts, and even in preclinical models of conditions like age-related hypogonadism and pulmonary fibrosis. The selective nature of FOXO4-DRI is particularly promising, suggesting a therapeutic window where senescent cells, which contribute to tissue dysfunction and inflammation, can be removed, potentially restoring tissue function and ameliorating age-related decline.
Senolytic peptides represent a class of compounds designed to clear senescent cells from the body. Cellular senescence is a state where cells cease to divide and accumulate, often secreting inflammatory factors that can damage surrounding tissues and contribute to aging-related diseases. FOXO4-DRI, a cell-penetrating peptide, has emerged as a leading candidate in this field due to its precise mechanism of action.作者：Y Huang·2021·被引用次数：51—In thisstudy, we tested the hypothesis thatFOXO4-DRItreatment can selectively remove senescent cells in expanded human chondrocytes, thus ... Unlike broader cytotoxic agents, FOXO4-DRI specifically targets the interaction between FOXO4 and p53. This interaction is crucial for maintaining the senescent state, and by disrupting it, the peptide triggers programmed cell death (apoptosis) exclusively in senescent cells.Cleara Biotech Launches to Develop Senolytic Therapies ...
Early research, including studies on cell cultures and animal models, has highlighted the potential of FOXO4-DRI. For instance, it has been shown to selectively remove senescent cells from in vitro expanded human chondrocytes, a finding with implications for osteoarthritis research. Furthermore, studies have explored its role in conditions like keloid formation and age-related testosterone secretion decline, where senescent cells are implicatedUS20200255489A1 - Novel Senolytic Peptides. The development of FOXO4-DRI as a novel senolytic peptide is a testament to the ongoing efforts to translate fundamental research on aging into tangible therapeutic interventions.
The landscape of FOXO4-DRI research is dynamic, with a growing number of studies exploring its therapeutic potential. Investigations are not only focused on its senolytic activity but also on its broader impact on tissue health and disease. For example, research has examined how FOXO4-DRI can target myofibroblasts and potentially reverse diseases characterized by their accumulation. Its ability to induce apoptosis in senescent cancer cells, as demonstrated in some studies, also opens avenues for cancer therapy research, particularly in combination with other treatments2025年7月1日—...senolytic peptide FOXO4-DRI. Here, we solve the solution NMR ... Dive into theresearchtopics of 'The disordered p53 transactivation ....
The specific disruption of the FOXO4-p53 interaction by FOXO4-DRI is a key area of ongoing investigation. Molecular modeling studies have been instrumental in understanding this interaction at a structural level, aiding in the design of even more effective senolytic peptides. While many studies are preclinical, the consistent demonstration of FOXO4-DRI's selective action and its potential to ameliorate senescence-related pathologies underscore its significance in the field of senotherapeutics. The ongoing research aims to further validate these findings and pave the way for potential human trials作者：U Tripathi·2021·被引用次数：7—...peptide FOXO4-DRIin both in-vitro and in-vivostudies. Le et al. [6] ... a) Two alternative approaches for designing asenolytic peptideto ....
The continued exploration of FOXO4-DRI peptide in senolytic study holds considerable promise for addressing age-related diseases and improving overall healthspan. As research progresses, a deeper understanding of its optimal dosage, delivery methods, and potential side effects will be crucial.FOXO4-DRI induces keloid senescent fibroblast apoptosis ... While the current focus is on preclinical studies, the consistent results across various models suggest that FOXO4-DRI could become a valuable tool in the future of regenerative medicine and gerontology. The ongoing scientific inquiry into this peptide is critical for unlocking its full therapeutic potential and developing innovative treatments for conditions linked to cellular senescence.
Join the newsletter to receive news, updates, new products and freebies in your inbox.